RenovoRx Net Income
| RNXT Stock | USD 0.99 0.04 4.21% |
As of the 7th of February, RenovoRx holds the Risk Adjusted Performance of 0.0113, coefficient of variation of 29625.69, and Semi Deviation of 5.47. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of RenovoRx, as well as the relationship between them.
RenovoRx Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 27.6607 | Revenue | Earnings Share (0.36) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.9 M | -8.3 M | |
| Net Loss | -8.9 M | -9.3 M | |
| Net Loss | -7.9 M | -8.3 M | |
| Net Loss | (0.43) | (0.45) |
RenovoRx | Net Income | Build AI portfolio with RenovoRx Stock |
The evolution of Net Income for RenovoRx provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how RenovoRx compares to historical norms and industry peers.
Latest RenovoRx's Net Income Growth Pattern
Below is the plot of the Net Income of RenovoRx over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in RenovoRx financial statement analysis. It represents the amount of money remaining after all of RenovoRx operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is RenovoRx's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in RenovoRx's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.81 M) | 10 Years Trend |
|
Net Income |
| Timeline |
RenovoRx Net Income Regression Statistics
| Arithmetic Mean | (5,505,343) | |
| Coefficient Of Variation | (44.66) | |
| Mean Deviation | 2,161,267 | |
| Median | (3,839,000) | |
| Standard Deviation | 2,458,435 | |
| Sample Variance | 6T | |
| Range | 6.4M | |
| R-Value | (0.79) | |
| Mean Square Error | 2.4T | |
| R-Squared | 0.63 | |
| Significance | 0.0001 | |
| Slope | (386,012) | |
| Total Sum of Squares | 96.7T |
RenovoRx Net Income History
Other Fundumenentals of RenovoRx
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
RenovoRx Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for RenovoRx is extremely important. It helps to project a fair market value of RenovoRx Stock properly, considering its historical fundamentals such as Net Income. Since RenovoRx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of RenovoRx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of RenovoRx's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will RenovoRx introduce new products? Factors like these will boost the valuation of RenovoRx. Anticipated expansion of RenovoRx directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about RenovoRx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of RenovoRx is measured differently than its book value, which is the value of RenovoRx that is recorded on the company's balance sheet. Investors also form their own opinion of RenovoRx's value that differs from its market value or its book value, called intrinsic value, which is RenovoRx's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because RenovoRx's market value can be influenced by many factors that don't directly affect RenovoRx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between RenovoRx's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding RenovoRx should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, RenovoRx's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
RenovoRx 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to RenovoRx's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of RenovoRx.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in RenovoRx on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding RenovoRx or generate 0.0% return on investment in RenovoRx over 90 days. RenovoRx is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, OSR Holdings, Lipocine, and SeaStar Medical. RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid t... More
RenovoRx Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure RenovoRx's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess RenovoRx upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.88 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 29.68 | |||
| Value At Risk | (6.54) | |||
| Potential Upside | 8.33 |
RenovoRx Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for RenovoRx's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as RenovoRx's standard deviation. In reality, there are many statistical measures that can use RenovoRx historical prices to predict the future RenovoRx's volatility.| Risk Adjusted Performance | 0.0113 | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.55) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0038 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of RenovoRx's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
RenovoRx February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0113 | |||
| Market Risk Adjusted Performance | 0.0138 | |||
| Mean Deviation | 4.16 | |||
| Semi Deviation | 5.47 | |||
| Downside Deviation | 5.88 | |||
| Coefficient Of Variation | 29625.69 | |||
| Standard Deviation | 5.7 | |||
| Variance | 32.54 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.55) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0038 | |||
| Maximum Drawdown | 29.68 | |||
| Value At Risk | (6.54) | |||
| Potential Upside | 8.33 | |||
| Downside Variance | 34.57 | |||
| Semi Variance | 29.88 | |||
| Expected Short fall | (4.93) | |||
| Skewness | (0.54) | |||
| Kurtosis | 3.13 |
RenovoRx Backtested Returns
Currently, RenovoRx is dangerous. RenovoRx maintains Sharpe Ratio (i.e., Efficiency) of 0.0266, which implies the firm had a 0.0266 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for RenovoRx, which you can use to evaluate the volatility of the company. Please check RenovoRx's Coefficient Of Variation of 29625.69, risk adjusted performance of 0.0113, and Semi Deviation of 5.47 to confirm if the risk estimate we provide is consistent with the expected return of 0.15%. RenovoRx has a performance score of 2 on a scale of 0 to 100. The company holds a Beta of 2.41, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, RenovoRx will likely underperform. RenovoRx right now holds a risk of 5.8%. Please check RenovoRx potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if RenovoRx will be following its historical price patterns.
Auto-correlation | -0.37 |
Poor reverse predictability
RenovoRx has poor reverse predictability. Overlapping area represents the amount of predictability between RenovoRx time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of RenovoRx price movement. The serial correlation of -0.37 indicates that just about 37.0% of current RenovoRx price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.37 | |
| Spearman Rank Test | 0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
RenovoRx Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, RenovoRx reported net income of (8.81 Million). This is 102.58% lower than that of the Biotechnology sector and 112.58% lower than that of the Health Care industry. The net income for all United States stocks is 101.54% higher than that of the company.
RenovoRx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RenovoRx's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of RenovoRx could also be used in its relative valuation, which is a method of valuing RenovoRx by comparing valuation metrics of similar companies.RenovoRx is currently under evaluation in net income category among its peers.
RenovoRx Current Valuation Drivers
We derive many important indicators used in calculating different scores of RenovoRx from analyzing RenovoRx's financial statements. These drivers represent accounts that assess RenovoRx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of RenovoRx's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 86.5M | 42.5M | 47.1M | 30.5M | 35.0M | 33.3M | |
| Enterprise Value | 71.3M | 38.2M | 46.0M | 23.6M | 27.1M | 25.8M |
RenovoRx Institutional Holders
Institutional Holdings refers to the ownership stake in RenovoRx that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of RenovoRx's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing RenovoRx's value.| Shares | Hightower Advisors, Llc | 2025-06-30 | 40 K | Kestra Advisory Services, Llc | 2025-06-30 | 35.5 K | Ubs Group Ag | 2025-06-30 | 30 K | Northern Trust Corp | 2025-06-30 | 26.8 K | State Street Corp | 2025-06-30 | 26.2 K | Two Sigma Securities, Llc | 2025-06-30 | 21.8 K | Hrt Financial Llc | 2025-06-30 | 20.6 K | Adar1 Capital Management Llc | 2025-06-30 | 19.9 K | Affinity Capital Advisors, Llc | 2025-06-30 | 13.3 K | Aigh Capital Management, Llc | 2025-06-30 | 3.5 M | Awm Investment Company Inc | 2025-06-30 | 1.9 M |
RenovoRx Fundamentals
| Return On Equity | -1.47 | ||||
| Return On Asset | -0.68 | ||||
| Operating Margin | (12.03) % | ||||
| Current Valuation | 25.67 M | ||||
| Shares Outstanding | 36.65 M | ||||
| Shares Owned By Insiders | 4.63 % | ||||
| Shares Owned By Institutions | 20.25 % | ||||
| Number Of Shares Shorted | 541.45 K | ||||
| Price To Book | 4.39 X | ||||
| Price To Sales | 37.55 X | ||||
| Revenue | 43 K | ||||
| Gross Profit | 629 K | ||||
| EBITDA | (10.97 M) | ||||
| Net Income | (8.81 M) | ||||
| Cash And Equivalents | 10.77 M | ||||
| Cash Per Share | 1.19 X | ||||
| Total Debt | 278 K | ||||
| Current Ratio | 10.01 X | ||||
| Book Value Per Share | 0.22 X | ||||
| Cash Flow From Operations | (9.12 M) | ||||
| Short Ratio | 1.63 X | ||||
| Earnings Per Share | (0.36) X | ||||
| Target Price | 6.05 | ||||
| Number Of Employees | 10 | ||||
| Beta | 1.31 | ||||
| Market Capitalization | 34.85 M | ||||
| Total Asset | 8.12 M | ||||
| Retained Earnings | (50.22 M) | ||||
| Working Capital | 5.92 M | ||||
| Net Asset | 8.12 M |
About RenovoRx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze RenovoRx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RenovoRx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RenovoRx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.